GLP-1 Drug Interactions: What to Tell Your Prescriber

A GLP-1 intake form that only asks your weight and a few checkboxes isn't doing the job a real medical visit does. GLP-1 drugs change how your stomach empties and how your body handles blood sugar, and both of those mechanisms interact with other medications you might already be taking. Here's what the current FDA-approved labeling for Wegovy, Ozempic, Mounjaro, and Zepbound actually says you and your prescriber need to discuss.

The core mechanism: delayed gastric emptying

Every GLP-1 approved for weight management slows how fast your stomach empties into your small intestine. That's part of how they reduce appetite — but it also means anything you swallow moves through your system differently. The Zepbound label states plainly: "ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications"¹. The Wegovy label carries near-identical language and gives a concrete example: in a drug-interaction study, levothyroxine (a common thyroid medication) exposure increased by 33% when taken alongside semaglutide². If you take a narrow-therapeutic-index medication — one where too much or too little makes a real clinical difference — this is exactly the kind of interaction your prescriber needs to know about before you start.

Insulin and sulfonylureas: the hypoglycemia risk

If you're managing type 2 diabetes alongside weight loss, this is the interaction that matters most. Both the Wegovy and Zepbound labels instruct prescribers to "consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk" of hypoglycemia¹². Sulfonylureas (like glipizide or glimepiride) are the most common insulin secretagogues prescribed for type 2 diabetes. Combining either of those drug classes with a GLP-1 without a dose adjustment is a known cause of dangerously low blood sugar — tell your prescriber about every diabetes medication you're on, not just insulin.

Oral contraceptives — a specific, dated warning

This one is easy to miss because it isn't intuitive. Mounjaro's label gives explicit guidance: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation"³. The concern is the same gastric-emptying mechanism — delayed absorption can reduce how reliably an oral contraceptive works during the weeks right after you start or step up your dose. If you're relying on the pill for contraception and starting a GLP-1, this is a conversation to have before, not after.

Why the contraceptive warning is easy to miss

The oral-contraceptive interaction is worth dwelling on because it's the kind of detail a rushed intake is most likely to skip. It doesn't apply once and then stop mattering — the 4-week caution window resets every time your dose steps up, per Mounjaro's label, which means it can apply repeatedly over your first few months of treatment, not just at the start³. A program that mentions it once at signup and never again isn't giving you the full picture; ask your prescriber to flag it again at each dose increase if it's relevant to you.

Ozempic carries the same core interactions as Wegovy

If you're prescribed Ozempic rather than Wegovy — same molecule, different approved indication — the interaction profile doesn't change. Ozempic's label carries the same gastric-emptying caution for oral medications and the same instruction to consider reducing insulin or insulin-secretagogue doses to manage hypoglycemia risk⁴. Don't assume a different brand name means a different interaction checklist; for semaglutide products specifically, it doesn't.

Interactions don't require you to avoid a GLP-1 — just to disclose

None of the interactions above are automatic disqualifiers. A prescriber who knows you're on levothyroxine can space out your dosing or monitor thyroid levels more closely. A prescriber who knows you're on a sulfonylurea can adjust that medication's dose before you start rather than after a hypoglycemic episode forces the issue. The entire point of disclosure is that these are manageable with the right information up front — they only become a real problem when nobody involved knows to look for them.

What a real intake should ask

Based on what the labeling flags, a prescriber worth trusting should ask about:

- Any diabetes medications, especially insulin or sulfonylureas - Thyroid medication or other narrow-therapeutic-index drugs - Oral hormonal contraceptives - Any other oral medication you rely on for a chronic condition, since gastric-emptying changes are a class effect, not specific to one drug

If a signup flow doesn't ask any of this, that's a red flag about the medical rigor behind the program — not just a shortcut. It's the same concern we raise about slow, careful titration in GLP-1 dosing and titration: how the schedule actually works, and about honest side-effect disclosure in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported — a program that skips one of these conversations often skips the others too.

Where this fits your provider decision

We score real medical oversight — not just a prescription rubber-stamp — as part of our Value Score methodology. A cheap program with a thin intake isn't actually cheaper if it misses an interaction that costs you a hospital visit or an unplanned pregnancy. Check how thorough each program's intake is in our provider reviews, and compare pricing on our semaglutide and tirzepatide rankings once you've confirmed the medical process is real.

Alcohol, existing kidney disease, and cardiovascular history are worth disclosing too

Several more items belong on the same disclosure list even though they aren't drug interactions in the strict pharmacological sense. Regular alcohol use is worth mentioning both for its own effects and because it shares a rare risk — pancreatitis — with the GLP-1 class itself; see GLP-1 and alcohol: what the evidence actually shows. If you have type 2 diabetes with existing chronic kidney disease, that's now relevant to which GLP-1 and which indication your prescriber reaches for, not just a side note — see GLP-1 and kidney disease: the FLOW trial evidence. And if you have established cardiovascular disease, an on-label indication may apply to your prescription specifically — see GLP-1 and cardiovascular risk: the SELECT trial evidence. A history of gastroparesis or pancreatitis specifically is also worth flagging directly, for reasons covered in GLP-1 lawsuits: what the claims allege, and what the evidence actually shows.

Bring your full medication list

The single most useful thing you can do before your first visit is write down every prescription, over-the-counter drug, and supplement you take. None of the interactions above require you to avoid a GLP-1 — they require your prescriber to know about them so they can adjust doses or timing accordingly.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.